This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Histologically confirmed PanNEN.
New and existing PanNEN participants will be eligible (any grade, any stage, any age > 18 years).
Participants willing and able to comply with the study procedures.
Inability to provide informed consent.
Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
Active hematologic malignancy.
History of allogenic bone marrow transplant or stem cell transplant.
University of California, San Francisco
Lead sponsor
University of California Pancreatic Cancer Consortium (UCPCC)
Collaborator